The Personalized Cancer Medicine Initiative at Vanderbilt
|
|
|
- Katrina Eaton
- 6 years ago
- Views:
Transcription
1 The Personalized Cancer Medicine Initiative at Vanderbilt October 26, 2009 William Pao, MD, PhD Assistant Director, Personalized Cancer Medicine Vanderbilt-Ingram Cancer Center
2 Cancer in the United States, 2009 New Cases Deaths Lung 219,440 Lung 159,390 Breast 192,370 Colorectal 49,920 Prostate 192,280 Breast 40,170 Colorectal 146,970 Prostate 27,360 Jemal et al 09
3 Traditional View of Lung Cancer Small Cell Lung Cancer (SCLC) Large Squam Adeno Non-Small Cell Lung Cancer (NSCLC): Adenocarcinoma Squamous cell carcinoma Large cell carcinoma Small
4 30 Yrs Research: Effect of Standard Chemotherapy in NSCLC Has Reached a Plateau 1207 pts Response rate 19% Median TTP 3.7 mos Median OS 8 mos Schiller et al 02
5 Iressa and Tarceva Related Agents that Target EGFR ATP
6 Dramatic Response to Gefitinib
7 EGFR Mutations Associated with Sensitivity to Gefitinib/Erlotinib EGF ligand binding Tyrosine kinase autophos TM K DFG Y Y Y Y GXGXXG K DFG L L Exon: LREA G719A/C deletion L858R L861Q Lynch et al 04; Paez et al 04; Pao et al 04
8 Clinical Predictors NSCLC 10% Female 18% Adenocarcinoma 12% Never smoker 30% Molecular Predictors KRAS mutn <1% EGFR mutn >70% Predictors of Response to Gefitinib/Erlotinib
9 Probability of progression-free survival Probability of progression-free survival EGFR mutation positive Rnd Ph III Trial: Iressa Pan ASian Study (IPASS: Gefitinib vs Chemo, upfront) EGFR mutation negative 1.0 Gefitinib (n=132) Carboplatin / paclitaxel (n=129) 1.0 Gefitinib (n=91) Carboplatin / paclitaxel (n=85) HR (95% CI) = 0.48 (0.36, 0.64) p< No. events gefitinib: 97 No. events Chemo: HR (95% CI) = 2.85 (2.05, 3.98) p< No. events gefitinib: 88 No. events Chemo: At risk : Gefitinib C/P Months Months Gefitinib RR 71% Gefitinib RR 1% Mok et al 09
10 Fusions Involving the ALK Tyrosine Kinase Define Another Subset of NSCLC (Soda et al 07) 20 ALK EML KINASE E13a;A20 E20;A20 E6a/b;A20 E14;A20 E2a/b;A20 E13b;A20 E14;A20 E15;A20 E18;A20 KINASE KINASE KINASE KINASE KINASE KINASE KINASE KINASE KINASE V1 V2 V3a/b V4 V5a/b V6 V7 V4 V5
11 % of best change from baseline One patient had clinical progression and discontinued without radiographic confirmation. Kwak et al PASCO 09 Tumor Responses to PF for NSCLC Evaluable Patients with ALK Fusions Tumor Size Change Duration of Response (Weeks) Green - PR Blue - SD Black - PD 4+
12 Traditional View of Lung Cancer Small Cell Lung Cancer (SCLC) Large Squam Adeno Non-Small Cell Lung Cancer (NSCLC): Adenocarcinoma Squamous cell carcinoma Large cell carcinoma Small
13 Squam 2009: Lung Adenoca- Multiple Molecular Subsets ALK fusion BRAF PIK3CA MEK1 HER2 KRAS EGFR ROS fusion PDGFR amp Large Small Adeno Unknown
14 2009: Lung Adenoca- Multiple Molecular Subsets ALK fusion ROS fusion BRAF PIK3CA PDGFR amp MEK1 HER2 KRAS EGFR Mutations associated with drug sensitivity G719X, exon 19 del, L858R, L861Q Mutations associated with 1ry drug resistance exon 20 dup Mutations associated with 2ry drug resistance L747S, D761Y, T854A, T790M MET amplification Unknown
15 Melanoma: Also Comprised of Clinically Relevant Molecular Subsets
16 (Carvajal et al PASCO 09) Phase II Trial of Imatinib in KIT-Mutant Melanoma
17 Phase II Trial of BRAF Inhibitor (PLX-4302) in BRAF-Mutant Melanoma (Flaherty, Sosman, Puzanov et al PASCO 09)
18 %Change From Baseline (Sum of Lesion Size) Interim Best Overall Response in Extension Cohort Patients % Response Rate (18 PRs and 1 CR) M1a M1b M1c (RECIST cutoff for PR, 30%) -100 n=27 Evaluable Patients As of 8/21/09
19 BRAF V600E Melanoma Patient PET Scan at Baseline and Day +15 After PLX4032 Treatment at 960 mg BID
20 Cancers Driven by Mutant Kinases and Targeted by Specific Kinase Inhibitors Disease Target Kinase inhibitor Chronic myelogenous leukemia BCR-ABL Imatinib Gastrointestinal stromal tumor Mutant KIT or PDGFRa Imatinib Lung adenocarcinoma Mutant EGFR Gefitinib/Erlotinib Lung adenocarcinoma EML4-ALK ALK inhibitors (in development) Melanoma Mutant BRAF BRAF inhibitors (in development) Melanoma Mutant KIT Imatinib
21 Ongoing Efforts to Sequence Cancer Genomes/Identify Drug Targets
22 Goals of the VICC PCMI To establish reflex testing of common clinically relevant genetic alterations in lung cancers and melanomas. To develop a clinically-applicable high-throughput molecular genotyping facility for rarer genetic variants. To develop bioinformatic algorithms to report genetic results in the electronic medical record in ways that are clinically useful for practicing oncologists. Collaboration among Depts of Medicine, Pathology, BioInformatics, and VICC Sounds simple, but requires high level of collaboration/coordination
23 Aim 1 To establish reflex testing of common clinically relevant genetic alterations in lung cancers and melanomas. Melanoma BRAF KIT Lung adenocarcinoma EGFR KRAS ALK
24 Aim 2 To develop a clinically-applicable highthroughput molecular genotyping facility for rarer genetic variants.
25 Version 1: 36 Somatic Point Mutations in 8 Genes Relevant totargeted Therapy in Lung Adenocarcinoma EGFR Position AA mutant Nucleotide mutant p.g719c c.2155g>t G719 p.g719s c.2155g>a p.g719a c.2156g>c T790 p.t790m c.2369c>t L858 p.l858r c.2573t>g L861 p.l861q c.2582t>a KRAS G12 G13 Q61 p.g12c p.g12s p.g12r p.g12v p.g12a p.g12d p.g13c p.g13s P.G13R p.g13d p.g13a p.q61k p.q61r p.q61l p.q61h p.q61h c.34g>t c.34g>a c.34g>c c.35g>t c.35g>c c.35g>a c.37g>t c.37g>a c.37g>c c.38g>a c.38g>c c.181c>a c.182a>g c.182a>t c.183a>t c.183a>c BRAF Position AA mutant Nucleotide mutant G469 p.g469a c.1406g>c L597 p.l597v c.1789c>g V600 p.v600e c.1799t>a NRAS Q61 p.q61k p.q61l p.q61r c.181c>a c.182a>t c.182a>g PIK3CA H1047 p.h1047r c.3140a>g E542 p.e542k c.1624g>a E545 p.e545k c.1633g>a MEK1 (MAP2K1) Q56 p.q56n c.167a>c K57 p.k57n c.171g>t D67 p.d67n c.199g>a AKT1 E17 p.e17k c.49g>a PTEN R233 p.r233* c.697c>t
26 Lung Adenocarcinoma Comprehensive Screen (5 Panels)
27 NRAS G12 p.g12c p.g12s p.g12r p.g12v c.34g>t c.34g>a c.34g>c c.35g>t p.g12a c.35g>c p.g12d c.35g>a p.g12n c.34_35gg>aa G13 p.g13a c.38g>c p.g13v c.38g>t p.g13r c.37g>t p.g13d c.38g>a Q61 p.q61e c.181c>g p.q61h c.183a>t p.q61h c.183a>c p.q61l p.q61l p.q61l c.182a>t c.181_182ca>tt c.182_183aa>tg p.q61k p.q61k c.181c>a c.180_181ac>ta p.q61p c.182a>c p.q61r p.q61r p.q61r c.182a>g c.180_181ac>ta c.182_183aa>gg Version 1: 45 Somatic Point Mutations in 5 Genes Relevant to Targeted Therapy in Melanoma BRAF Position AA Nucleotide p.v600r c.1798_1799gt>ag p.v600k c.1798_1799gt>aa p.v600e c.1799t>a V600 p.v600e p.v600m p.v600g V600D (call E) c1799_1800 TG>AA c1798g>a c1799t>g c1799_1800 TG>AT CTNNB1 (B-CAT) p.s45p c133t>c S45 p.s45f c134c>t p.s45y c134c>a S37 p.s37f c.110c>t p.s37y c110c>a KIT K642 p.k642e c.1924a>g L576 p.l576p c.1727t>c W557 p.w557r c.1669t>c p.w557r c.1669t>a V559 p.v559a c.1676t>c p.v559d c.1676t>a D816 p.d816h c.2446g>c GNAQ Q209 p.q209p p.q209l p.q209l c.626a>c c.626a>t c.625_626ca>tt
28 Melanoma Comprehensive Screen (5 Panels) NRAS_G13 (38R) BRAF _V600 (1799) NRAS_Q61 (182) B-CATS45 (134R) B-CAT_S37 (110) NRAS_G13 (37R) BRAF_V600 (1798) NRAS_Q61 (183R) KIT_V559 (1676) B-CAT_S45 (133R) NRAS_G12 (35) KIT_W557 (1669) KIT_L576 (1727) KIT_D816 (2446) GNAQ_Q209 (626) NRAS_G12 (34R) KIT_K642 (1924) NRAS_Q61 (181) A: Green T: Red G: Blue C: Black
29 PCR-Based Sizing Assays for Insertions/Deletions in Lung Adenocarcinoma H1650: E19del = 15 bp del E20ins = WT H20ins = WT E20i E19d H20i Lung Ca Sample: E19del = WT E20ins = 6 bp ins H20ins = WT H1781: E19del = WT E20ins = 3 bp ins H20ins = WT
30 Aim 3 To develop bioinformatic algorithms to report genetic results in the electronic medical record in ways that are clinically useful for practicing oncologists. The propensity to prescribe
31 Current Medical Oncology Provider White Board
32 Proposed Medical Oncology Provider White Board Demographics Diagnosis/ Stage GW 55AF NSCLC Adenocarcinoma Stage IV Relevant Biomarkers Disease Status EGFR+ Metastatic Erlotinib since 6/7/08 Current Tx CBC Che m Imaging 11:33 11:33 Last CT CAP 8/7/09 Trial Status Consider 2 nd -gen EGFR TKI if POD JD 68WF DS 45WM NSCLC Adenocarcinoma Stage II NSCLC Adenocarcinoma Stage IV KRAS+ Recurrent Metastatic Carboplatin/ Paclitaxel s/p 2 cycles; started 7/15/ Last CT CAP 7/12/09 ALK+ Metastatic Untreated - - Today - pending Consider KRAS trial; unlikely to respond to EGFR TKI Consider ALK trial WP 55M Malignant Melanoma Stage II BRAF+ Recurrent Metastatic PLX-0432 since 08/12/ Last CT CAP 9/22/09 - DS 42M Malignant Melanoma Stage IV KIT+ Metastatic Interferonalfa2b - - Last CT CAP 7/7/09 Consider imatinib
33 Summary/Future Directions Personalized Cancer Medicine Initiative launched at VICC Multiplex genotyping platforms nearly developed Implementation into CLIA labs planned Reflex testing already initiated for some mutations Consents written Molecular results to be placed in chart Bioinformatics to provide clinical decision support Importantly, PCMI will serve as a template to move forward with other cancers, genetic results
34 Potential Benefits of Tailoring Therapy According to the Genetic Makeup of Tumors Using EGFR mutations in NSCLC as an example: Make more informed medical decisions Higher probability of desired outcomes Reduced probability of negative side effects Chemo: intravenous, nausea, vomiting, hair loss, neutropenia, kidney failure Iressa/Tarceva: oral, rash, diarrhea
35 Potential Benefits of Tailoring Therapy According to the Genetic Makeup of Tumors Reduced healthcare costs Standard Approach: 2 cycles carbo/paclitaxel/bevacizumab $29,170 (wait 6 weeks to determine response) followed by 2 cycles of pemetrexed $21,868 (wait 6 weeks to determine response) Total: $51,038 Molecularly Tailored Approach: Multiplex mutation test $2,000 (>70% chance of response if known EGFR mutation) Erlotinib (90d) $13,671 Total: $17,671
36 Acknowledgements Pao Lab MarKeesa Duke Laurel Fohn Katie Hutchinson Zengliu Su Paula Woods VICC Jennifer Pientepol Pathology Cheryl Coffin Cindy Vnencak-Jones Medicine David Johnson Jeff Sosman Bioinformatics Dan Masys Mia Levy Russ Waitman MGH A. John Iafrate Funding Anonymous Foundation VICC CCSG TJ Martell Foundation
Recent advances in the molecular pathology of lung cancer: role of EGFR and KRAS mutation testing in treatment selection
ASIP 2009 USCAP Companion Meeting Molecular Pathology for the Practicing Pathologist Recent advances in the molecular pathology of lung cancer: role of EGFR and KRAS mutation testing in treatment selection
July 2015 Assay ID Assay Name Gene COSMIC ID Amino acid change Nucleotide change Wild type allele (VIC label) Mutant allele (FAM label)
July 2015 Assay ID Assay Name Gene COSMIC ID Amino acid change Nucleotide change Wild type allele (VIC label) Mutant allele (FAM label) p AHLJ090 AKT1_33765 AKT1 33765 p.e17k c.49g>a C T 2 AHBKFRM BRAF_473
Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making
Next Generation Sequencing in Clinical Practice: Impact on Therapeutic Decision Making November 20, 2014 Capturing Value in Next Generation Sequencing Symposium Douglas Johnson MD, MSCI Vanderbilt-Ingram
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
Changing demographics of smoking and its effects during therapy
Changing demographics of smoking and its effects during therapy Egbert F. Smit MD PhD. Dept. Pulmonary Diseases, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands Smoking prevalence adults
Supplementary Online Content
Supplementary Online Content Kris MG, Johnson BE, Berry LD, et al. Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs. JAMA. doi:10.1001/jama.2014.3741 etable 1. Trials
Biomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007
Biomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007 Bruce E. Johnson, MD Dana-Farber Cancer Institute, Brigham and Women s Hospital, and Harvard
Osamu Tetsu, MD, PhD Associate Professor Department of Otolaryngology-Head and Neck Surgery School of Medicine, University of California, San
Osamu Tetsu, MD, PhD Associate Professor Department of Otolaryngology-Head and Neck Surgery School of Medicine, University of California, San Francisco Lung Cancer Classification Pathological Classification
Next Generation Lung Cancer Medicine
Next Generation Lung Cancer Medicine 12 th International Lung Cancer Congress 4 th Annual Addario Lectureship Award Carlsbad, CA August 12, 2011 William Pao, MD, PhD Ingram Associate Professor of Cancer
Molecular Targets in Lung Cancer
Molecular Targets in Lung Cancer Robert Ramirez, DO, FACP Thoracic and Neuroendocrine Oncology November 18 th, 2016 Disclosures Consulting and speaker fees for Ipsen Pharmaceuticals, AstraZeneca and Merck
7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview
Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon
Whole Exome Sequenced Characteristics
Supplementary Tables Supplementary Table 1: Patient characteristics of 45 whole exome sequenced HNSCC tumors Whole Exome Sequenced Characteristics Tumors (n=45) Age, years Median (range) 61.0 (19-90) Sex,
Targeted therapy in lung cancer : experience of NIO-RABAT
Targeted therapy in lung cancer : experience of NIO-RABAT I.ELGHISSASSI, H.ERRIHANI Medical oncology department, NIO- RABAT 02-05- 2012, FEZ In Morocco, lung cancer is the most common tumor among men At
Corporate Medical Policy
Corporate Medical Policy Molecular Analysis for Targeted Therapy for Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: molecular_analysis_for_targeted_therapy_for_non_small_cell_lung_cancer
Lung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD. Mount Carrigain 2/4/17
Lung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD Mount Carrigain 2/4/17 Histology Adenocarcinoma: Mixed subtype, acinar, papillary, solid, micropapillary, lepidic
Personalized Medicine: Lung Biopsy and Tumor
Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Elizabeth H. Moore, MD Personalized Medicine: Lung Biopsy and Tumor Mutation Testing Genomic testing has resulted in a paradigm shift in the
Optimum Sequencing of EGFR targeted therapy in NSCLC. Dr. Sema SEZGİN GÖKSU Akdeniz Univercity, Antalya, Turkey
Optimum Sequencing of EGFR targeted therapy in NSCLC Dr. Sema SEZGİN GÖKSU Akdeniz Univercity, Antalya, Turkey Lung cancer NSCLC SCLC adeno squamous EGFR ALK ROS1 BRAF HER2 KRAS EGFR Transl Lung Cancer
Joachim Aerts Erasmus MC Rotterdam, Netherlands. Drawing the map: molecular characterization of NSCLC
Joachim Aerts Erasmus MC Rotterdam, Netherlands Drawing the map: molecular characterization of NSCLC Disclosures Honoraria for advisory board/consultancy/speakers fee Eli Lilly Roche Boehringer Ingelheim
EGFR ctdna Testing. Andrew Wallace 21/09/2015 Genomic Diagnostics Laboratory St. Mary s Hospital, Manchester
EGFR ctdna Testing Andrew Wallace 21/09/2015 Genomic Diagnostics Laboratory St. Mary s Hospital, Manchester ctdna & EGFR Testing in NSCLC EGFR ctdna testing Non-invasive - patients too sick/biopsy or cytology
Supplementary Table 1. PIK3CA mutation in colorectal cancer
Liao X et al. PIK3CA Mutation in Colorectal Cancer. Page 1 Supplementary Table 1. PIK3CA mutation in colorectal cancer Exon Domain Nucleotide change* Amino acid change* cases 9 Helical c.1621t>a p.e541t
Lung Cancer Case. Since the patient was symptomatic, a targeted panel was sent. ALK FISH returned in 2 days and was positive.
Lung Cancer Case Jonathan Riess, M.D. M.S. Assistant Professor of Medicine University of California Davis School of Medicine UC Davis Comprehensive Cancer Center 63 year-old woman, never smoker, presents
Personalized Healthcare Update
Dr. Kai - Oliver Wesche Market Development Manager, Personalized Healthcare QIAGEN Personalized Healthcare Update Pioneering Personalized Medicine through Partnering TOMTOVOK BKM120 Zelboraf QIAGEN partners:
EGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
Targeted therapies for advanced non-small cell lung cancer. Tom Stinchcombe Duke Cancer Insitute
Targeted therapies for advanced non-small cell lung cancer Tom Stinchcombe Duke Cancer Insitute Topics ALK rearranged NSCLC ROS1 rearranged NSCLC EGFR mutation: exon 19/exon 21 L858R and uncommon mutations
EGFR Mutation-Positive Acquired Resistance: Dominance of T790M
Treatment of EGFR Mutation-Positive Acquired Resistance: T790M+ or T790M- H. Jack West, MD Swedish Cancer Institute, Seattle, WA EGFR Mutation-Positive Acquired Resistance: Dominance of T790M Yu, Clin
Role of the pathologist in the diagnosis and mutational analysis of lung cancer Professor J R Gosney
Role of the pathologist in the diagnosis and mutational analysis of lung cancer Professor J R Gosney Consultant Thoracic Pathologist Royal Liverpool University Hospital Disclosure JRG is a paid advisor
The Rapidly Changing World of EGFR Mutation-Positive Acquired Resistance
The Rapidly Changing World of EGFR Mutation-Positive Acquired Resistance H. Jack West, MD Swedish Cancer Institute Seattle, WA GRACE Targeted Therapies Forum September 16, 2017 Cleveland, OH EGFR Mutation-Positive
Targeted therapy in NSCLC: do we progress? Prof. Dr. V. Surmont. Masterclass 27 september 2018
Targeted therapy in NSCLC: do we progress? Prof. Dr. V. Surmont Masterclass 27 september 2018 Outline Introduction EGFR TKI ALK TKI TKI for uncommon driver mutations Take home messages The promise of
Inhibidores de EGFR Noemi Reguart, MD, PhD Hospital Clínic Barcelona IDIPAPS
Inhibidores de EGFR Noemi Reguart, MD, PhD Hospital Clínic Barcelona IDIPAPS Driver Mutations to Classify Lung Cancer Unknown 36% KRAS 25% EGFR 15% ALK 4% HER2 2% Double Mut 2% BRAF 2% PIK3CA
Treatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Data on first-line Overcoming T790M
Management Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors
Management Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors Conor E. Steuer, MD Assistant Professor The Winship Cancer Institute of Emory University July 27, 2017 1 Lung Cancer One
Liquid biopsy in lung cancer: The EGFR paradigm
Liquid biopsy in lung cancer: The EGFR paradigm Lynette M. Sholl, M.D. Brigham and Women s Hospital Dana Farber Cancer Institute Department of Pathology Boston, MA Disclosure of Relevant Financial Relationships
Medical Policy An independent licensee of the Blue Cross Blue Shield Association
Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer Page 1 of 52 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Molecular Analysis for Targeted
Selecting the right patients for the right trials.
Selecting the right patients for the right trials. Paul Waring Professor of Pathology University of Melbourne June 21, 2011 RCPA Genetics short course Drug development challenges. Current model of drug
MICROSCOPY PREDICTIVE PROFILING
Immunomodulatory therapy in NSCLC: a year into clinical practice Professor J R Gosney Consultant Thoracic Pathologist Royal Liverpool University Hospital Disclosure JRG is a paid advisor to and speaker
State of the Art in Tumor Profiling
State of the Art in Tumor Profiling Dora Dias-Santagata, PhD, FACMG ddiassantagata@partners.org Translational Research Laboratory Massachusetts General Hospital Harvard Medical School Boston, MA Disclosures
Supplementary Table 2. Identified causative mutations and/or mutation candidates.
Supplementary Table 2. Identified causative mutations and/or mutation candidates. Nonsense mutations base change aa change Average depth Result of next generation in 432 patient Hereditary form of the
Supplementary Figure 1
Supplementary Figure 1 A B HEC1A PTEN +/+ HEC1A PTEN -/- 16 HEC1A PTEN -/- 22 PTEN RAD51 % Cells with RAD51 foci 40 -IR +IR 30 20 10 * *! TUBULIN 0 HEC1A PTEN+/+ HEC1A PTEN-/- 16 HEC1A PTEN-/- 22 C D 1.0
K-Ras signalling in NSCLC
Targeting the Ras-Raf-Mek-Erk pathway Egbert F. Smit MD PhD Dept. Pulmonary Diseases Vrije Universiteit VU Medical Centre Amsterdam, The Netherlands K-Ras signalling in NSCLC Sun et al. Nature Rev. Cancer
Frequency of Epidermal Growth Factor Mutation Status and Its Effect on Outcome of Patients with Adenocarcinoma of the Lung
Journal of Cancer Therapy, 2014, 5, 1012-1020 Published Online September 2014 in SciRes. http://www.scirp.org/journal/jct http://dx.doi.org/10.4236/jct.2014.511106 Frequency of Epidermal Growth Factor
Liquid biopsy: the experience of real life case studies
Liquid biopsy: the experience of real life case studies 10 th September 2018 Beatriz Bellosillo Servicio de Anatomía Patológica Hospital del Mar, Barcelona Agenda Introduction Experience in colorectal
PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy
PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy Prognostic versus predictive Prognostic: In presence of the biomarker patient outcome
D Ross Camidge, MD, PhD
i n t e r v i e w D Ross Camidge, MD, PhD Dr Camidge is Director of the Thoracic Oncology Clinical Program and Associate Director for Clinical Research at the University of Colorado Cancer Center in Aurora,
Frequency(%) KRAS G12 KRAS G13 KRAS A146 KRAS Q61 KRAS K117N PIK3CA H1047 PIK3CA E545 PIK3CA E542K PIK3CA Q546. EGFR exon19 NFS-indel EGFR L858R
Frequency(%) 1 a b ALK FS-indel ALK R1Q HRAS Q61R HRAS G13R IDH R17K IDH R14Q MET exon14 SS-indel KIT D8Y KIT L76P KIT exon11 NFS-indel SMAD4 R361 IDH1 R13 CTNNB1 S37 CTNNB1 S4 AKT1 E17K ERBB D769H ERBB
Phase II Cancer Trials: When and How
Phase II Cancer Trials: When and How Course for New Investigators August 9-12, 2011 Learning Objectives At the end of the session the participant should be able to Define the objectives of screening vs.
Do You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement. Reference Slides Introduction
Do You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement Reference Slides Introduction EML4-ALK Fusion Oncogene Key Driver in 3% to 7% NSCLC Inversion or Translocation
Multi-Center Phase III Clinical Trials and NCI Cooperative Groups. Dr. John E. Niederhuber Director, National Cancer Institute July 1, 2008
Multi-Center Phase III Clinical Trials and NCI Cooperative Groups Dr. John E. Niederhuber Director, National Cancer Institute July 1, 2008 Phase II Trial of Paclitaxel by 96-Hour Continuous Infusion Plus
presentation session & clinical Keith T. Flaherty, M.D. Abramson Cancer Center of the University of Pennsylvania
Melanoma: highlights from the oral presentation session & clinical science symposium at ASCO 2009 Keith T. Flaherty, M.D. Abramson Cancer Center of the University of Pennsylvania Abstracts to be discussed
NCCN Non-Small Cell Lung Cancer V Meeting June 15, 2018
Guideline Page and Request Illumina Inc. requesting to replace Testing should be conducted as part of broad molecular profiling with Consider NGS-based assays that include EGFR, ALK, ROS1, and BRAF as
2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
IRESSA (Gefitinib) The Journey. Anne De Bock Portfolio Leader, Oncology/Infection European Regulatory Affairs AstraZeneca
IRESSA (Gefitinib) The Journey Anne De Bock Portfolio Leader, Oncology/Infection European Regulatory Affairs AstraZeneca Overview The Drug The Biomarker and Clinical Trials Sampling Lessons Learned The
EGFR, Lung Cancer and Cytology. Maureen F. Zakowski, M.D. Lung cancer is one of the most lethal cancers in Western countries and in Japan.
EGFR, Lung Cancer and Cytology Maureen F. Zakowski, M.D. Lung cancer is one of the most lethal cancers in Western countries and in Japan. It is histopathologically divided into two major sub-groups: Small
Beyond ALK and EGFR: Novel molecularly driven targeted therapies in NSCLC Federico Cappuzzo AUSL della Romagna, Ravenna, Italy
Beyond ALK and EGFR: Novel molecularly driven targeted therapies in NSCLC Federico Cappuzzo AUSL della Romagna, Ravenna, Italy Oncogenic drivers in NSCLC Certain tumours arise as a result of aberrant activation
Supplementary Figure 1
Supplementary Figure 1 Supplementary Figure 1: Generation of cetuximab-resistant cells and analysis of singlecell clones. Cetuximab-sensitive cells (LIM1215 and OXCO-2) were chronically treated with cetuximab
Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Suresh S. Ramalingam, MD Director of Thoracic Oncology Associate Professor Emory University Atlanta,
Dr. Andres Wiernik. Lung Cancer
Dr. Andres Wiernik Lung Cancer Lung Cancer Facts - Demographics World Incidence: 1 8 million / year World Mortality: 1 6 million / year 5-year survival rates vary from 4 17% depending on stage and regional
Supplementary Materials for
www.sciencetranslationalmedicine.org/cgi/content/full/3/75/75ra26/dc1 Supplementary Materials for Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors Lecia V. Sequist,*
KEY FINDINGS 1. Potential Clinical Benefit in Non-Small Cell Lung Cancer with Gefitinib, Erlotinib, Afatinib due to EGFR E746_A750del. 2. Potential Cl
PATIENT INFO SAMPLE REFERING PHYSICIAN COPY TO (if different from ordering) Name: John Smith Date Collected: 10/23/2016 Name: Oncologist, M.D. Name: Pathologist, M.D. DOB: 04/22/1937 Date Received: 10/24/2016
Targeted therapy in non-small cell lung cancer: a focus on epidermal growth factor receptor mutations
Review Article Page 1 of 5 Targeted therapy in non-small cell lung cancer: a focus on epidermal growth factor receptor mutations Gérard A. Milano Oncopharmacology Unit, EA 3836 UNS, Centre Antoine Lacassagne,
Corporate Medical Policy
Corporate Medical Policy Proteomic Testing for Targeted Therapy in Non-Small Cell Lung File Name: Origination: Last CAP Review: Next CAP Review: Last Review: proteomic_testing_for_targeted_therapy_in_non_small_cell_lung_cancer
Personalized Genetics
Personalized Genetics Understanding Your Genetic Test Results Tracey Evans, MD September 29, 2017 Genetics 101 Punnett Square Genetic Pedigree 2 Genetics 101 Punnett Square Genetic Pedigree 3 It s not
HOW TO GET THE MOST INFORMATION FROM A TUMOR BIOPSY
HOW TO GET THE MOST INFORMATION FROM A TUMOR BIOPSY 7 TH Annual New York Lung Cancer Symposium Saturday, November 10, 2012 William D. Travis, M.D. Attending Thoracic Pathologist Memorial Sloan Kettering
1.Basis of resistance 2.Mechanisms of resistance 3.How to overcome resistance. 13/10/2017 Sara Redaelli
Dott.ssa Sara Redaelli 13/10/2017 1.Basis of resistance 2.Mechanisms of resistance 3.How to overcome resistance Tumor Heterogeneity: Oncogenic Drivers in NSCLC The Promise of Genotype-Directed Therapy
Disclosures Genomic testing in lung cancer
Disclosures Genomic testing in lung cancer No disclosures Objectives Understand how FISH and NGS provide complementary data for the evaluation of lung cancer Recognize the challenges of performing testing
1. Q: What has changed from the draft recommendations posted for public comment in November/December 2011?
Frequently Asked Questions (FAQs) in regard to Molecular Testing Guideline for Selection of Lung Cancer Patients for EGFR and ALK Tyrosine Kinase Inhibitors 1. Q: What has changed from the draft recommendations
Slide 1. Slide 2. Slide 3. Disclosures. Personalized Medicine for Advanced NSCLC in East Asia. No conflicts related to this presentation
Slide 1 12 th International Lung Cancer Conference Personalized Medicine for Advanced NSCLC in East Asia Masahiro Tsuboi, M.D., Ph.D. Group Chair, Lung Cancer Surgical Study Group in Japan Clinical Oncology
IntelliGENSM. Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community.
IntelliGENSM Integrated Oncology is making next generation sequencing faster and more accessible to the oncology community. NGS TRANSFORMS GENOMIC TESTING Background Cancers may emerge as a result of somatically
Slide 1. Slide 2. Slide 3. Individualized Therapy in Lung Cancer : Where are we in 2011? Notable Advances in Cancer Research in the last 2 years
Slide 1 Individualized Therapy in Lung Cancer : Where are we in 2011? Giorgio V. Scagliotti University of Torino Department of Clinical & Biological Sciences giorgio.scagliotti@unito.it Slide 2 Notable
Individualized Cancer Therapy: Chemotherapy Resistance Testing before Therapy
Individualized Cancer Therapy: Chemotherapy Resistance Testing before Therapy 1 st st International Oncological Conference Wrocław, October 6 th, 2012 Dr. Frank Kischkel Individualized Cancer Therapy:
Treatment of EGFR-Mutation+ NSCLC in 1st- and 2nd-Line
Treatment of EGFR-Mutation+ NSCLC in 1st- and 2nd-Line Martin Reck David F. Heigener Department of Thoracic Oncology Hospital Grosshansdorf Germany Identification of driver mutation in tumor specimens
MET skipping mutation, EGFR
New NSCLC biomarkers in clinical research: detection of MET skipping mutation, EGFR T790M, and other important biomarkers Fernando López-Ríos Laboratorio de Dianas Terapéuticas Hospital Universitario HM
Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer.
Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer Reference Slides ALK Rearrangement in NSCLC ALK (anaplastic lymphoma kinase) is a receptor
Response and resistance to BRAF inhibitors in melanoma
Response and resistance to BRAF inhibitors in melanoma Keith T. Flaherty, M.D. Massachusetts General Hospital Cancer Center Disclosures Roche/Genentech: consultant GlaxoSmithKline: consultant BRAF mutations
TARGETED THERAPY FOR LUNG CANCER. Patient and Caregiver Guide
TARGETED THERAPY FOR LUNG CANCER Patient and Caregiver Guide TARGETED THERAPY FOR LUNG CANCER Patient and Caregiver Guide TABLE OF CONTENTS Why Targeted Therapy?...2 Lung Cancer Basics...2 Changes in
ALCHEMIST. Adjuvant Lung Cancer Enrichment Marker Identification And Sequencing Trials
ALCHEMIST Adjuvant Lung Cancer Enrichment Marker Identification And Sequencing Trials What is ALCHEMIST? ALCHEMIST is 3 integrated trials testing targeted therapy in early stage lung cancer: l A151216:
Phase II Cancer Trials: When and How
Phase II Cancer Trials: When and How Course for New Investigators August 21-23, 2013 Acknowledgment Elizabeth Eisenhauer for some slides! Learning Objectives At the end of the session the participant should
Personalised Healthcare (PHC) with Foundation Medicine (FMI) Fatma Elçin KINIKLI, FMI Turkey, Science Leader
Personalised Healthcare (PHC) with Foundation Medicine (FMI) Fatma Elçin KINIKLI, FMI Turkey, Science Leader Agenda PHC Approach Provides Better Patient Outcome FMI offers Comprehensive Genomic Profiling,
Molecular Pathology and Lung Cancer. A. John Iafrate MD-PhD Department of Pathology Massachusetts General Hospital Boston, MA
Molecular Pathology and Lung Cancer A. John Iafrate MD-PhD Department of Pathology Massachusetts General Hospital Boston, MA aiafrate@partners.org Disclosures Preliminary patent application NGS AMP Fusion
Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer
Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer Policy Number: 2.04.45 Last Review: 3/2018 Origination: 3/2013 Next Review: 3/2019 Policy Blue Cross and Blue Shield of Kansas City
SUBJECT: GENOTYPING - EPIDERMAL GROWTH
MEDICAL POLICY SUBJECT: GENOTYPING - EPIDERMAL GROWTH Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature
LUNG CANCER TREATMENTS UPDATED MAY What you need to know about... targeted therapy
LUNG CANCER TREATMENTS UPDATED MAY 2018 What you need to know about... targeted therapy foreword About LUNGevity LUNGevity is the largest national lung cancer-focused nonprofit, changing outcomes for people
Personalised cancer care Information for Medical Specialists. A new way to unlock treatment options for your patients
Personalised cancer care Information for Medical Specialists A new way to unlock treatment options for your patients Contents Optimised for clinical benefit 4 Development history 4 Full FIND IT panel vs
Quale sequenza terapeutica nella malattia EGFR+
Trattamento della malattia avanzata oncogene-addicted Quale sequenza terapeutica nella malattia EGFR+ Chiara Bennati AUSL della Romagna Ravenna, Italy A matter of fact Outline Can we improve PFS/OS with
Individualized therapy in lung cancer Where are we in 2012?
UNIVERSITY OF OF TORINO DEPARTMENT OF ONCOLOGY Individualized therapy in lung cancer Where are we in 2012? Giorgio V. Scagliotti University of Torino Professor of Medical Oncology Department of Oncology
The Role of Next Generation Sequencing in Solid Tumor Mutation Testing
The Role of Next Generation Sequencing in Solid Tumor Mutation Testing Allie H. Grossmann MD PhD Department of Pathology, University of Utah Division of Anatomic Pathology & Oncology, ARUP Laboratories
Case Presentation. Case, continued. Case, continued. Case, continued. Lung Cancer in 2014: The New Paradigm
Lung Cancer in 2014: The New Paradigm James J. Stark, MD, FACP Professor of Clinical Internal Medicine Eastern Virginia Medical School August 20, 2014 Case Presentation 62 year old man, former smoker,
Treatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and Manchester University Hospital Manchester, UK Outline Data on first-line Overcoming T790M mutation
CLINICAL MEDICAL POLICY
Policy Name: Policy Number: Responsible Department(s): CLINICAL MEDICAL POLICY Molecular Tumor Markers for Non-Small Cell Lung Cancer (NSCLC) MP-061-MD-DE Medical Management Provider Notice Date: 10/15/2018;
A View to the Future: The Development of Targeted Therapy for Melanoma. Michael Davies, M.D., Ph.D.
A View to the Future: Science to Survivorship Symposium September 26, 2009 The Development of Targeted Therapy for Melanoma Michael Davies, M.D., Ph.D. Assistant Professor, Melanoma Medical Oncology How
Giorgio V. Scagliotti Università di Torino Dipartimento di Oncologia
Giorgio V. Scagliotti Università di Torino Dipartimento di Oncologia giorgio.scagliotti@unito.it Politi K & Herbst R. Clin. Cancer Res. 2015; 21:2213 Breast Colorectal Gastric/GE Junction Tumor Type Head
LONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012
Disease background LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Erlotinib for the third or fourth-line treatment of NSCLC January 2012 Lung cancer is the second most common cancer in the UK (after breast),
VeriStrat Poor Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End
AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress VeriStrat Poor Patients Show
Molecular Testing in Lung Cancer
Molecular Testing in Lung Cancer Pimpin Incharoen, M.D. Assistant Professor, Thoracic Pathology Department of Pathology, Ramathibodi Hospital Genetic alterations in lung cancer Source: Khono et al, Trans
Genetic Alteration Panels
TM Genetic Alteration Panels GENETIC ALTERATION PANELS Table of Contents AKT Genetic Alteration Panel (ATCC No. TCP-1029 )...1 BRAF Genetic Alteration Panel (ATCC No. TCP-1032 )...5 EGFR Genetic Alteration
Medical Policy. MP Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer
Medical Policy MP 2.04.45 BCBSA Ref. Policy: 2.04.45 Last Review: 10/30/2017 Effective Date: 10/30/2017 Section: Medicine Related Policies 2.04.115 Molecular Panel Testing of Cancers to Identify Targeted
Molecular Analysis for Targeted Therapy for Non- Small-Cell Lung Cancer Section 2.0 Medicine Subsection 2.04 Pathology/Laboratory
2.04.45 Molecular Analysis for Targeted Therapy for Non- Small-Cell Lung Cancer Section 2.0 Medicine Subsection 2.04 Pathology/Laboratory Effective Date November 26, 2014 Original Policy Date November
Current and future applications of Molecular Pathology. Kathy Walsh Clinical Scientist NHS Lothian
Current and future applications of Molecular Pathology Kathy Walsh Clinical Scientist NHS Lothian Molecular Pathology in Solid tumours Cancer type Genes tested Purpose Associated treatments Non small cell
EXAMPLE. - Potentially responsive to PI3K/mTOR and MEK combination therapy or mtor/mek and PKC combination therapy. ratio (%)
Dr Kate Goodhealth Goodhealth Medical Clinic 123 Address Road SUBURBTOWN NSW 2000 Melanie Citizen Referring Doctor Your ref Address Dr John Medico 123 Main Street, SUBURBTOWN NSW 2000 Phone 02 9999 9999
ALK Fusion Oncogenes in Lung Adenocarcinoma
ALK Fusion Oncogenes in Lung Adenocarcinoma Vincent A Miller, MD Associate Attending Physician, Thoracic Oncology Service Memorial Sloan-Kettering Cancer Center New York, New York The identification of
LUNG CANCER. pathology & molecular biology. Izidor Kern University Clinic Golnik, Slovenia
LUNG CANCER pathology & molecular biology Izidor Kern University Clinic Golnik, Slovenia 1 Pathology and epidemiology Small biopsy & cytology SCLC 14% NSCC NOS 4% 70% 60% 50% 63% 62% 61% 62% 59% 54% 51%